Parade Technologies Acquires Spectra7 Majority Assets to Enhance High-Speed Data Transmission Capabilities and Boost Connectivity Market Opportunities
With the purchase of the majority of Spectra7's assets, Parade Technologies is positioned to further strengthen its global leadership in high-speed connectivity solutions. The purchase will enable Parade to both continue marketing Spectra7's existing advanced active cable product portfolio and to leverage Spectra7's technology in new high speed solutions. Parade anticipates that Spectra7's cutting-edge SiGe-technology, achieving data speeds of 112 Gbps and higher, will provide valuable support for Parade's efforts to expand into high-growth markets such as data centers, AI-powered computing, and next-generation consumer electronics. In addition, as part of the acquisition, a significant number of Spectra7's employees will join Parade Technologies, ensuring continuity of technical expertise and customer support. This strategic purchase will further empower Parade's ongoing efforts to deliver faster, more energy-efficient signal integrity connectivity solutions that meet the evolving demands of today's data-driven world.
The transaction, which is subject to customary closing conditions, is expected to close in the second quarter of 2025.
ABOUT PARADE TECHNOLOGIES, LTD.
Parade Technologies, Ltd. is a leading supplier of mixed-signal ICs for a variety of popular display and high-speed interface standards used in computers, consumer electronics and display panels. The fabless semiconductor company was founded in 2005 and publicly listed on Taipei Exchange ('TPEx') in 2011 (stock code: 4966). Parade's portfolio of IC products serves the growing demand for HDMI™, DisplayPort™, SATA, and USB ICs for display, storage and interface applications.
In addition to being a technology innovator, Parade is an active participant and leader in industry standards-setting organizations. Parade Technologies, Inc., a wholly owned US-based subsidiary of Parade Technologies, Ltd., is a member of VESA (Video Electronics Standard Association). Parade Technologies, Inc. has made key contributions to the development of VESA's DisplayPort™ digital video interface standard.
Parade leverages its close relationships with market leading Tier-1 OEMs to develop ICs that provide unique system capabilities. Many of the company's devices integrate proprietary technologies that offer superior system signal integrity, advanced system integration and enhanced power efficiency. As a result of the company's 'standards-plus' design philosophy, Parade ICs have been designed into products offered by nearly every leading computer and display vendor worldwide. ( https://www.paradetech.com/)
ABOUT SPECTRA7 MICROSYSTEMS INC.
Spectra7 Microsystems Inc. is a leader in high-performance analog semiconductors for powering the AI revolution in broadband connectivity markets, hyperscale data centers, and Spatial Computing. Spectra7 is based in San Jose, California with a design center in Cork, Ireland and a technical support location in Dongguan, China. ( https://www.spectra7.com/)
INDUSTRY KEYWORD: SEMICONDUCTOR HARDWARE DATA MANAGEMENT AUDIO/VIDEO TECHNOLOGY
SOURCE: Parade Technologies, Ltd.
Copyright Business Wire 2025.
PUB: 03/09/2025 08:00 PM/DISC: 03/09/2025 08:03 PM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
SugarCRM Named to Constellation ShortList for Top Midmarket CRM Suites
DENVER--(BUSINESS WIRE)-- SugarCRM, provider of the award-winning intelligence-driven sales automation platform, today announced it has been named to the Constellation ShortList™ for Midmarket CRM Suites in Q3 2025. The Constellation ShortList™ portfolio highlights the key players when considering technology investments in key areas and is designed to provide guidance on rapidly changing requirements and customer needs and demands. The Midmarket CRM Suites ShortList was compiled based on Constellation client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Constellation defines midmarket organizations as those that typically have from 250 to 1,000 employees and generate between $250 million and $1 billion in annual revenues. According to the research, in the midmarket CRM space, buyers typically seek one or more products in a suite to support sales force automation, service and support, marketing solutions, and commerce capabilities. Buyers expect analytics to be pervasive, integrated, and easy to use. Sugar Sell, sales-i, Market, and Serve are all part of SugarCRM's platform designed to unify sales, marketing and service through intuitive AI-powered capabilities. Together, these solutions break down the silos that often exist within a business, ensuring a cohesive and efficient approach to customer relationship management and customer success. 'This Constellation ShortList recognizes the strengths of our AI-powered CRM platform,' said David Roberts, SugarCRM Chief Executive Officer. 'Today's organizations demand more than data and insights; they want CRM solutions to direct sellers and customer-facing teams to the right next steps. Sugar delivers AI-powered sales technology that simplifies the complexity that comes from hundreds of customers and thousands of products, improving the productivity and effectiveness of a typical seller.' 'As AI reshapes the business landscape, organizations are under increasing pressure to realize meaningful transformation,' said R 'Ray' Wang, CEO and Founder at Constellation Research. 'In this era of accelerated change, Constellation's ShortList is designed to help companies identify top-performing solutions that drive efficiency and innovation.' Click here to learn more about Sugar's AI-driven solutions for CRM. About the Constellation ShortList Constellation Research advises leaders on leveraging disruptive technologies to achieve business model transformation and streamline business processes. Products and services named to the Constellation ShortList meet the threshold criteria for this category as determined through client inquiries, partner conversations, customer references, vendor selection projects, market share, and internal research. The portfolio is updated at least once per year as the analyst team deems necessary based on market conditions. Disclaimer: Constellation Research does not endorse any solution or service named in its research. About SugarCRM SugarCRM offers software solutions that help marketing, sales, and service teams reach peak efficiency through better automation, data, and intelligence so they can achieve a real-time, reliable view of each customer. Sugar's platform provides leading technology in the sales automation, marketing automation, and customer service fields with one goal in mind: to make the hard things easier. Thousands of companies in over 120 countries rely on Sugar by letting the platform do the work. Headquartered in the San Francisco Bay Area, Sugar is backed by Accel-KKR. For more information about SugarCRM, visit:
Yahoo
43 minutes ago
- Yahoo
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or 'ZyVersa'), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, reports financial results for the quarter ended June 30, 2025, and highlights progress toward achieving key value-building milestones. 'I am pleased to announce that we are well positioned to achieve our near-term development milestones,' said Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President. "In June and July 2025, we closed two financing transactions providing access to $12 million in capital to advance development of our highly differentiated drug therapies for kidney and inflammatory diseases, each of which target untargeted pathways to advance care for these serious conditions. Regarding our kidney disease drug VAR 200, in mid-June we initiated an open-label Phase 2a trial in patients with DKD. VAR 200 uniquely targets lipid accumulation in the kidney's filtration system that triggers inflammation, fibrosis, and progressive kidney damage leading to renal failure if not addressed. Preliminary data are expected in Q4-2025, with final results anticipated H1-2026. The data will provide insights for developing a larger Phase 2a/b protocol in patients with FSGS, our lead indication. Based VAR 200's unique mechanism of action, we were asked and agreed to provide drug and regulatory support under FDA-authorized Emergency Compassionate Use to treat a patient at the University of Miami Miller School of Medicine who has ApoCII amyloidosis, a very rare, life-threatening disease which mainly affects the kidney. Concerning our inflammasome inhibitor IC 100, we are making progress toward IND submission. Preparation is underway with the University of Miami School of Medicine to initiate an IND-enabling preclinical study in a diet-induced obesity (DIO) animal model in Q4-2025. A phase 1 trial in overweight healthy subjects at risk for certain cardiometabolic conditions will be initiated shortly following IND clearance. IC 100 uniquely targets inhibition of the ASC inflammasome component rather than the NLRP3 sensor molecule. By targeting ASC, IC 100 uniquely inhibits multiple inflammasome pathways and their associated ASC specks to alleviate perpetuation and spread of inflammation that damages tissues and organs causing numerous diseases and their progression. We appreciate your support for our efforts to develop groundbreaking drugs to improve patients' health and quality of life.' PIPELINE UPDATE Cholesterol Efflux Mediator™ VAR 200 Kidney Disease (Global Drug Market: $18 Billion in 2024; $30 Billion Projected by 2034) The first patient is expected to be treated in a phase 2a clinical trial in patients with DKD in Q3-2025, with interim results in Q4-2025. The intent of the study is to obtain renal patient proof-of-concept for VAR 200 prior to initiating a larger phase 2a/b for VAR 200's lead indication, FSGS. The DKD study will evaluate VAR 200's safety and efficacy (% change in proteinuria from baseline to week 12) in eight patients with type 2 diabetes who have diabetic kidney disease. Inflammasome ASC Inhibitor IC 100 Inflammatory Diseases (Global Biologics Market: $105 Billion in 2024; $186 Billion Projected by 2034) Obesity with Cardiometabolic Complications In preparation for filing an IND for IC 100, a diet-induced obesity (DIO) mouse model study is expected to be initiated in partnership with University of Miami Miller School of Medicine Q4-2025. The study will evaluate the effects of IC 100 on body weight, body composition, and changes in cardiovascular, metabolic, and inflammatory parameters in comparison to semaglutide, and when administered concurrently with semaglutide. Following IND clearance, a phase 1 trial will be initiated with IC 100 in healthy overweight people (BMI: 27 – 30) at risk of cardiometabolic conditions to evaluate the safety of 3 different doses of IC 100, and to get a signal on the degree of weight loss, and changes in cardiometabolic biomarkers that can be expected with each dose. Second Quarter 2025 FINANCIAL RESULTS Cash on hand was $0.1 million as of June 30, 2025. On July 8, 2025, we closed a $2.05M warrant inducement transaction from a current investor. Research and development expenses were $0.4 million for the three months ended June 30, 2025, a decrease of $0.3 million or 42.2% from the three months ended June 30, 2024. The decrease is attributable to lower CRO fees of $0.1 million for VAR 200, lower research and development consultant costs of $0.1 million resulting from fewer consultants, and lower pre-clinical costs of $0.1 million for IC 100, partially offset by an increase in VAR 200 manufacturing stability testing. General and administrative (G&A) expenses were $1.6 million for the three months ended June 30, 2025, a decrease of $0.4 million or 20.1% from the three months ended June 30, 2024. The decrease is primarily attributable to a decrease of $0.1 million in director and officer insurance premiums, a $0.1 million decrease in investor and public relations marketing expense, a $0.1 million decrease in professional fees from lower accounting and legal expense, and a decrease of $0.1 million in stock-based compensation expense resulting from fully amortized options in 2025. Decreased G&A expenses were partially offset by a $0.1 million increase in public company costs due to additional costs associated with our annual shareholder meeting and Nasdaq hearings. Net losses were approximately $2.2 million for the three months ended June 30, 2025, with an improvement of $0.6 million or 20% compared to a net loss of approximately $2.8 million, for the three months ended June 30, 2024. Based on our current operating plan, we expect our cash and cash equivalents will only be sufficient to fund operating expenses and capital expenditure requirements on a month-to-month basis. ZyVersa will need additional financing to support its continuing operations, pay for its current liabilities, and to meet its stated milestones. ZyVersa will seek to fund its operations and clinical activity through public or private equity, debt financings, or other sources which may include government grants, collaborations with third parties, or outstanding warrant exercises. ABOUT ZYVERSA THERAPEUTICS, INC. ZyVersa (OTCQB: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management's intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. ('ZyVersa') uses words such as 'anticipates,' 'believes,' 'plans,' 'expects,' 'projects,' 'future,' 'intends,' 'may,' 'will,' 'should,' 'could,' 'estimates,' 'predicts,' 'potential,' 'continue,' 'guidance,' and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa's ability to obtain the funding necessary to advance the development of our product candidates and maintain its business operations; plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa's planned preclinical and clinical trials; the timing of the availability of data from ZyVersa's preclinical and clinical trials; the timing of any planned investigational new drug application; ZyVersa's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa's product candidates; ZyVersa's commercialization, marketing and manufacturing capabilities and strategy; ZyVersa's ability to protect its intellectual property position; and ZyVersa's estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities. CORPORATE, MEDIA, IR CONTACT Karen CashmereChief Commercial Officerkcashmere@ ZYVERSA THERAPEUTICS, CONSOLIDATED BALANCE SHEETS June 30,2025 December 31,2024 (Unaudited) Assets Current Assets: Cash $ 72,086 $ 1,530,924 Prepaid expenses and other current assets 378,749 184,873 Vendor deposits 98,234 - Total Current Assets 549,069 1,715,797 In-process research and development 18,647,903 18,647,903 Vendor deposit 69,477 178,476 Deferred offering costs 374,662 57,238 Total Assets $ 19,641,111 $ 20,599,414 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 9,774,230 $ 9,337,267 Accrued expenses and other current liabilities 2,915,448 1,894,041 Total Current Liabilities 12,689,678 11,231,308 Deferred tax liability 851,659 851,659 Total Liabilities 13,541,337 12,082,967 Stockholders' Equity: Preferred stock, $0.0001 par value, 1,000,000 shares authorized: Series A preferred stock, 8,635 shares designated, 50 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Series B preferred stock, 5,062 shares designated, 5,062 shares issued and outstanding as of June 30, 2025 and December 31, 2024 1 1 Common stock, $0.0001 par value, 250,000,000 shares authorized; 4,873,463 and 2,508,198 shares issued as of June 30, 2025 and December 31, 2024, respectively, and 4,873,456 and 2,508,191 shares outstanding as of June 30, 2025 and December 31, 2024, respectively 487 251 Additional paid-in-capital 123,207,260 121,155,922 Accumulated deficit (117,100,806 ) (112,632,559 ) Treasury stock, at cost, 7 shares at June 30, 2025 and December 31, 2024 (7,168 ) (7,168 ) Total Stockholders' Equity 6,099,774 8,516,447 Total Liabilities and Stockholders' Equity $ 19,641,111 $ 20,599,414 ZYVERSA THERAPEUTICS, CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) For the Three Months Ended June 30, 2025 2024 Operating Expenses: Research and development $ 409,937 $ 709,049 General and administrative 1,634,195 2,044,929 Total Operating Expenses 2,044,132 2,753,978 Loss From Operations (2,044,132 ) (2,753,978 ) Other (Income) Expense: Interest expense 130,036 58 Change in fair value of equity payable 37,149 - Pre-Tax Net Loss (2,211,317 ) (2,754,036 ) Income tax benefit - (9,707 ) Net Loss $ (2,211,317 ) $ (2,763,743 ) Net Loss Per Share - Basic and Diluted $ (0.46 ) $ (3.31 ) Weighted Average Number of Common Shares Outstanding - Basic and Diluted 4,814,115 834,915
Business Wire
an hour ago
- Business Wire
Cameron Stephens Launches Accelerated Lending Program to Support Commercial Real Estate Loans Up To $15 Million
TORONTO--(BUSINESS WIRE)--Cameron Stephens Mortgage Capital Ltd. ('Cameron Stephens') is pleased to announce the launch of its new Accelerated Lending Program, designed to offer borrowers fast, flexible financing solutions for commercial real estate ('CRE') transactions up to $15 million. Built to meet the needs of today's market, the Accelerated Lending Program provides single advance inventory, term, bridge, and land loans, with a streamlined commitment process of under 15 days. The initiative targets borrowers who seek faster turnaround times and more flexible structuring outside of conventional lending channels. All transactions are funded directly through Cameron Stephens' internal mortgage funds—no need for multiple lenders or external syndication. This structure eliminates layers of approval, simplifies deal execution, and significantly reduces time to close. This new lending channel is powered by up to $500 million in discretionary capital from Cameron Stephens' mortgage funds, including Cameron Stephens Mortgage Trust (CSMT), Bay Street High Yield Fund (BSHY), and Western Canada High Yield Fund (WCHY), providing a direct and streamlined path from capital to borrower. 'We've built this program to move at the speed our borrowers need—no red tape, no delays, just smart capital deployed with precision,' said Steve Cameron, President and COO of Cameron Stephens. 'It's another way we're using our private capital platform to fill market gaps and support our clients through every stage of the real estate development cycle.' 'From a portfolio management perspective, this initiative enhances our ability to dynamically allocate capital across the Cameron Stephens funds,' added Katie Bonar, SVP, Investment Management. 'It allows us to seize short-duration lending opportunities that generate attractive risk-adjusted returns while maintaining the discipline and diversification our investors expect. It's smart capital, well-placed. Within the next six months we anticipate committing in excess of $100 million to this initiative.' With the Accelerated Lending platform, Cameron Stephens continues to expand its comprehensive suite of commercial real estate lending solutions—combining institutional underwriting with entrepreneurial agility and a simplified, accelerated path to funding. For more information or to submit a loan inquiry, please contact Katie Bonar, SVP Investment Management, Agent Level 2, at kbonar@ or call her at 416-899-9701. About Cameron Stephens Founded in 2004, Cameron Stephens is a leading Canadian real estate investment firm with nearly $4 billion in assets under administration. Cameron Stephens offers institutional and private investors strategic opportunities to invest in commercial real estate with consistent returns. The firm specializes in mortgage solutions through Cameron Stephens Mortgage Capital for developers across Canada. Established in 2021, Cameron Stephens Equity Capital provides equity opportunities for high-quality and strategically positioned developments. Leveraging deep market expertise and strong industry partnerships, Cameron Stephens is recognized as a key player in Canada's real estate investment landscape, aiming to deliver sustainable growth and financial success. For more information, visit Cameron Stephens Mortgage Capital Ltd. is licensed as a mortgage brokerage (Lic #10769) and administrator (Lic # 11807) in Ontario.
